Detection of IgG and IgE reactivity to BP180 using the ISAC® microarray system

British Journal of Dermatology

Volumn 168, Issue 6, 2013, Pages 1205-1214

  Pomponi, D ^a   Di Zenzo, G ^a   Zennaro, D ^a   Calabresi, V ^a   Eming, R ^b   Zuzzi, S ^a   Bernardi, M L ^a   Scala, E ^a   Mari, A ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BP180 ANTIGEN; EPITOPE; IMMOBILIZED PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; HUMAN; IMMUNODETECTION; IMMUNOREACTIVITY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOANTIGENS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFANT; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84878624118     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12161     Document Type: Article

References (44)

1. Di Zenzo G, Della Torre R, Zambruno G, et al. Bullous pemphigoid: from the clinic to the bench. Clin Dermatol 2012; 30: 3-16.
2. Zillikens D, Mascaro JM, Rose PA, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997; 109: 679-83.
3. Nishie W, Sawamura D, Goto M, et al. Humanization of autoantigen. Nat Med 2007; 13: 378-83.
4. Ujiie H, Shibaki A, Nishie W, et al. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J Immunol 2010; 184: 2166-74.
5. Dresow SK, Sitaru C, Recke A, et al. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol 2009; 160: 429-32.
6. Arbesman CE, Wypych JI, Reisman RE, et al. IgE levels in sera of patients with pemphigus or bullous pemphigoid. Arch Dermatol 1974; 110: 378-81.
7. Asbrink E, Hovmark A,. Serum IgE levels in patients with bullous pemphigoid and its correlation to the activity of the disease and anti-basement membrane zone antibodies. Acta Derm Venereol 1984; 64: 243-6.
8. Bernard P, Venot J, Constant F, et al. Blood eosinophilia as a severity marker for bullous pemphigoid. J Am Acad Dermatol 1987; 16: 879-81.
9. Messingham KA, Noe MH, Chapman MA, et al. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods 2009; 346: 18-25.
10. Iwata Y, Komura K, Kodera M, et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008; 144: 41-8.
11. Dopp R, Schmidt E, Chimanovitch I, et al. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000; 42: 577-83.
12. Nagel A, Lang A, Engel D, et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol 2010; 134: 320-30.
13. Fairley JA, Burnett CT, Fu CL, et al. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007; 127: 2605-11.
14. Zone JJ, Taylor T, Hull C, et al. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007; 127: 1167-74.
15. Di Zenzo G, Thoma-Uszynski S, Fontao L, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 2008; 128: 415-26.
16. Sakuma-Oyama Y, Powell AM, Oyama N, et al. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J Dermatol 2004; 151: 126-31.
17. Tsuji-Abe Y, Akiyama M, Yamanaka Y, et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci 2005; 37: 145-9.
18. Kromminga A, Sitaru C, Hagel C, et al. Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol 2004; 111: 146-52.
19. Thoma-Uszynski S, Uter W, Schwietzke S, et al. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol 2004; 122: 1413-22.
20. Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011; 147: 286-91.
21. Roussel A, Benichou J, Randriamanantany ZA, et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011; 147: 293-8.
22. Mariotti F, Grosso F, Terracina M, et al. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol 2004; 151: 1004-10.
23. Hiller R, Laffer S, Harwanegg C, et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J 2002; 16: 414-6.
24. Scala E, Alessandri C, Bernardi ML, et al. Cross-sectional survey on immunoglobulin E reactivity in 23 077 subjects using an allergenic molecule-based microarray detection system. Clin Exp Allergy 2010; 40: 911-21.
25. Scala E, Abeni D, Palazzo P, et al. Specific IgE toward allergenic molecules is a new prognostic marker in patients with Sézary syndrome. Int Arch Allergy Immunol 2012; 157: 159-67.
26. Zennaro D, Scala E, Pomponi D, et al. Proteomics plus genomics approaches in primary immunodeficiency: the case of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Clin Exp Immunol 2012; 167: 120-8.
27. Bernardi ML, Giangrieco I, Camardella L, et al. Allergenic lipid transfer proteins from plant-derived foods do not immunologically and clinically behave homogeneously: the kiwifruit LTP as a model. PLoS ONE 2011; 6: e27856.
28. Matsumura K, Amagai M, Nishikawa T, et al. The majority of bullous pemphigoid and herpes gestationis serum samples react with the NC16a domain of the 180-kDa bullous pemphigoid antigen. Arch Dermatol Res 1996; 288: 507-9.
29. Fania L, Caldarola G, Muller R, et al. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses. Clin Immunol 2012; 143: 236-45.
30. Deinhofer K, Sevcik H, Balic N, et al. Microarrayed allergens for IgE profiling. Methods 2004; 32: 249-54.
31. Fairley JA, Fu CL, Giudice GJ,. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid. J Invest Dermatol 2005; 125: 467-72.
32. Valenta R, Mittermann I, Werfel T, et al. Linking allergy to autoimmune disease. Trends Immunol 2009; 30: 109-16.
33. Feliciani C, Caldarola G, Kneisel A, et al. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses. Br J Dermatol 2009; 161: 306-12.
34. Wieland CN, Comfere NI, Gibson LE, et al. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol 2010; 146: 21-5.
35. Foureur N, Mignot S, Senet P, et al. Correlation between the presence of type-2 anti-pemphigoid antibodies and dementia in elderly subjects with no clinical signs of pemphigoid. Ann Dermatol Venereol 2006; 133: 439-43.
36. Hofmann SC, Otto C, Bruckner-Tuderman L, et al. Isolated NC16a-ELISA testing is of little value to identify bullous pemphigoid in elderly patients with chronic pruritus. Eur J Dermatol 2009; 19: 634-5.
37. Pawelec G,. Immunosenescence: impact in the young as well as the old? Mech Ageing Dev 1999; 108: 1-7.
38. Li B, Samanta A, Song X, et al. FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. Int Immunol 2007; 19: 825-35.
39. Hori S, Nomura T, Sakaguchi S,. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
40. Quaglino P, Antiga E, Comessatti A, et al. Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients. Arch Dermatol Res 2012; 304: 639-45.
41. Arakawa M, Dainichi T, Ishii N, et al. Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Exp Dermatol 2011; 20: 1022-4.
42. Seiberler S, Natter S, Hufnagl P, et al. Characterization of IgE-reactive autoantigens in atopic dermatitis. 2. A pilot study on IgE versus IgG subclass response and seasonal variation of IgE autoreactivity. Int Arch Allergy Immunol 1999; 120: 117-25.
43. Rubartelli A, Lotze MT,. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 2007; 28: 429-36.
44. Valenta R, Duchene M, Pettenburger K, et al. Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 1991; 253: 557-60.